Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v2.3.0.15
Condensed Consolidated Balance Sheets (USD $)
In Thousands
Sep. 30, 2011
Dec. 31, 2010
ASSETS    
Cash and cash equivalents $ 6,076 $ 8,691
Marketable securities 19,211 6,008
Prepaid expenses and other current assets 830 944
Total current assets 26,117 15,643
Property and equipment, net 409 271
Restricted cash and other assets 349 290
Total assets 26,875 16,204
LIABILITIES AND STOCKHOLDERS' EQUITY    
Accounts payable 305 252
Accrued clinical and development expenses 3,461 2,439
Accrued liabilities 1,621 823
Total current liabilities 5,387 3,514
Warrant liability 12,030 7,499
Deferred rent 4 248
Total liabilities 17,421 11,261
Commitments and contingencies (Note 6)    
Stockholders' equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding    
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 49,128,475 shares at September 30, 2011 and 33,702,242 shares at December 31, 2010 49 34
Additional paid-in capital 256,267 231,383
Accumulated other comprehensive gain (loss) (9) 1
Deficit accumulated during the development stage (246,853) (226,475)
Total stockholders' equity 9,454 4,943
Total liabilities and stockholders' equity $ 26,875 $ 16,204